Global Trial in APG2575 for Patients With CLL/SLL
Part of paid clinical trials in Tuscon, Arizona.
- Sponsor
- Ascentage Pharma Group Inc.
- Study ID
- NCT06104566
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- CLL/SLL
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- lisaftoclax +BTK inhibitor — DRUGlisaftolax + BTK inhibitor
- BTK inhibitor — DRUGBTK inhibitor
Study Details
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Key Dates
- First listed
- Oct 27, 2023
- Start date
- Dec 20, 2023
- Status verified
- Jun 2026
- Primary completion
- Dec 31, 2026
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 400 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Arm 1Combination therapy
- Active Comparator: Arm 2mono therapy
Primary Outcome Measure
PFS [ Time Frame: 12 months ]
Central Contacts
- Shanthi Marur, MD3017925062
- Yifan Zhai, MD301-549-6188
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Ascentage Investigative Site | Tuscon | Arizona | 85742 | - |
| Ascentage Investigative Site | Anaheim | California | 92805 | - |
| Ascentage Investigative Site | Jacksonville | Florida | 32224 | - |
| Ascentage Investigative Site | Miami Beach | Florida | 33140 | - |
| Ascentage Investigative Site | Peoria | Illinois | 61615 | - |
| Ascentage Investigative Site | Boston | Massachusetts | 02215 | - |
| Ascentage Investigative Site | Ann Arbor | Michigan | 48109 | - |
| Ascentage Investigative Site | Greenville | North Carolina | 27834 | - |
| Ascentage Investigative Site | Houston | Texas | 77030 | Nitin Jain, MD (PRINCIPAL_INVESTIGATOR) |
| Ascentage Investigative Site | Kingswood | Texas | 77339 | - |
| Ascentage Investigative Site | Richmond | Virginia | 23298 | - |
Find similar trials in Tuscon, AZ
Related Studies
- Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLLPHASE1 · Recruiting · Ascentage Pharma Group Inc. · Duarte, California
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.PHASE1 · Recruiting · Newave Pharmaceutical Inc · Durham, North Carolina
- LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of ThisPHASE2 · Recruiting · Zulfa Omer · Cincinnati, Ohio
- Study of Epcoritamab as a Consolidation Therapy in CLL/SLLPHASE2 · Recruiting · Zulfa Omer · Cincinnati, Ohio